Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Bertotti

Showing results (41-50 of 99) with videos related to

Pageof 10
Sort By:
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Cancer Research|January 23, 2014
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitorsPaolo Luraghi, Gigliola Reato, Elia Cipriano, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 6, 2019
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsValentina Belli, Nunzia Matrone, Stefania Napolitano, et al.
Molecular Oncology|March 2, 2023
MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axisErmes Candiello, Gigliola Reato, Federica Verginelli, et al.
Oncotarget|October 7, 2016
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitorsValerio Gelfo, Maria Teresa Rodia, Michela Pucci, et al.
Nature Communications|June 1, 2017
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancerClaudio Isella, Francesco Brundu, Sara E Bellomo, et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Science Translational Medicine|January 30, 2015
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapiesEugenia R Zanella, Francesco Galimi, Francesco Sassi, et al.
Pageof 10

Showing results (41-50 of 99) with videos related to

Sort By:
Pageof 10
Science Signaling|December 10, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Science Translational Medicine|February 5, 2016
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutationsSabrina Arena, Giulia Siravegna, Benedetta Mussolin, et al.
Science Signaling|December 31, 2009
Only a subset of Met-activated pathways are required to sustain oncogene addictionAndrea Bertotti, Mike F Burbridge, Stefania Gastaldi, et al.
Cancer Research|January 23, 2014
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitorsPaolo Luraghi, Gigliola Reato, Elia Cipriano, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 6, 2019
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer modelsValentina Belli, Nunzia Matrone, Stefania Napolitano, et al.
Molecular Oncology|March 2, 2023
MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axisErmes Candiello, Gigliola Reato, Federica Verginelli, et al.
Oncotarget|October 7, 2016
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitorsValerio Gelfo, Maria Teresa Rodia, Michela Pucci, et al.
Nature Communications|June 1, 2017
Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancerClaudio Isella, Francesco Brundu, Sara E Bellomo, et al.
Cancers|March 19, 2020
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal CancerAnnalisa Lorenzato, Alessandro Magrì, Vittoria Matafora, et al.
Science Translational Medicine|January 30, 2015
IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapiesEugenia R Zanella, Francesco Galimi, Francesco Sassi, et al.
Pageof 10